Cytokinetics (CYTK) Misses Q2 EPS by 20c, misses on revenue
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $69.58 -0.49%
EPS Growth %: +43.1%
Financial Fact:
Income tax benefit: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +43.1%
Financial Fact:
Income tax benefit: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.34), $0.20 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $5.67 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Can global equities keep rising? UBS sees these factors driving upside
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
